USANA Health Sciences (NYSE:USNA) Releases FY 2026 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.950-2.290 for the period, compared to the consensus earnings per share estimate of 1.950. The company issued revenue guidance of $925.0M-$1.0 billion, compared to the consensus revenue estimate of $938.7 million.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce”.

USANA Health Sciences Stock Up 3.4%

USNA stock traded up $0.63 during midday trading on Tuesday, reaching $19.19. The stock had a trading volume of 97,334 shares, compared to its average volume of 124,922. The firm has a market cap of $354.13 million, a price-to-earnings ratio of 34.89, a PEG ratio of 0.83 and a beta of 0.77. USANA Health Sciences has a twelve month low of $16.60 and a twelve month high of $38.32. The business has a fifty day simple moving average of $18.58 and a two-hundred day simple moving average of $19.73.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. The company had revenue of $250.22 million for the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, equities analysts predict that USANA Health Sciences will post 1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Joshua Foukas sold 4,461 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $21.34, for a total value of $95,197.74. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.82% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its holdings in USANA Health Sciences by 82.8% during the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company’s stock worth $589,000 after buying an additional 9,894 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of USANA Health Sciences in the 1st quarter valued at about $687,000. Russell Investments Group Ltd. raised its position in shares of USANA Health Sciences by 31.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,377 shares of the company’s stock valued at $408,000 after acquiring an additional 3,198 shares during the period. Quantbot Technologies LP raised its position in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after acquiring an additional 646 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in USANA Health Sciences during the 2nd quarter worth approximately $422,000. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.